Abstract: The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: A system includes a door and an air conditioning system. The door is configured to move between a closed state in which the door covers an aperture sized and configured to receive a cargo container and opened state in which the aperture is uncovered. The air conditioning system includes a heat exchanger and a mount. The heat exchanger is configured to direct conditioned air into the cargo container. The mount is connected to the heat exchanger and configured to locate the heat exchanger adjacent the aperture in the opened state and in the closed state of the door without interfering with movement of the door.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: A rail sweeper assembly includes a vehicle, a debris removal system, and a first conveyor system. The vehicle is configured to travel on a railroad track. The railroad track includes a pair of railroad rails. The debris removal system is rotatably coupled to the vehicle at a first location and configured to lift debris from the railroad track. The first conveyor system is rotatably coupled to the vehicle at a second location and configured to receive the debris from the debris removal system.

Abstract: The present disclosure generally relates to user interfaces and techniques for managing and visualizing sound reduction using a computer system. In accordance with some embodiments, the computer system displays a representation of a noise level including, in accordance with a sound reduction display option being enabled, a first indication of a noise level at a first time and a second indication of a noise level at a time different from the first time. In accordance with some embodiments, in accordance with a determination that the sound reduction display option is not enabled, an indication of a noise level at the first time that indicates the noise level.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: The present disclosure generally relates to user interfaces and techniques for managing and visualizing sound reduction using a computer system. In accordance with some embodiments, the computer system displays a representation of a noise level including, in accordance with a sound reduction display option being enabled, a first indication of a noise level at a first time and a second indication of a noise level at a time different from the first time. In accordance with some embodiments, in accordance with a determination that the sound reduction display option is not enabled, an indication of a noise level at the first time that indicates the noise level.

Abstract: The subject technology provides for pseudo random projection for machine learning compression. An apparatus determines a first data structure comprising pseudo random values and a second data structure comprising one or more learned values based on a target compression ratio of a first dimension associated with a first weight matrix to a second dimension. The apparatus generates the second weight matrix comprising the second data structure and a seed value associated with the first data structure. The second weight matrix may be generated based at least in part on the pseudo random values and the one or more learned values. The second weight matrix is a compressed version of the first weight matrix based on the target compression ratio. The apparatus also trains a neural network with the second weight matrix to produce a trained machine learning model.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

Abstract: The present disclosure relates to compounds of Formula (III): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: The present disclosure generally relates to user interfaces and techniques for managing audio exposure using a computer system (e.g., an electronic device). In accordance with some embodiments, the electronic device displays a graphical indication of a noise exposure level over a first period of time with an area of the graphical indication that is colored to represent the noise exposure level, the color of the area transitioning from a first color to a second color when the noise exposure level exceeds a first threshold. In accordance with some embodiments, the electronic device displays noise exposure levels attributable to a first output device type and a second output device type and, in response to selecting a filtering affordance, visually distinguishes a set of noise exposure levels attributable to the second output device type.

Abstract: A computer-implemented method of channel change detection and overlay detection for a broadcast output, the computer-implemented method comprises providing a broadcast stream for a display; dividing the display into one or more regions, and selecting at least one of the one or more regions; based on the selected one or more regions, determining a first content associated with the broadcast stream; at a time associated with an insertion point for a second content, determining whether the determined first content associated with the broadcast stream matches a target content associated with insertion of the second content in the broadcast stream at the insertion point; for the first content not matching the target content, blocking the insertion of the second content; and for the first content not matching the target content, performing the insertion of the second content.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: A computer-implemented method of channel change detection and overlay detection for a broadcast output, the computer-implemented method comprises providing a broadcast stream for a display; dividing the display into one or more regions, and selecting at least one of the one or more regions; based on the selected one or more regions, determining a first content associated with the broadcast stream; at a time associated with an insertion point for a second content, determining whether the determined first content associated with the broadcast stream matches a target content associated with insertion of the second content in the broadcast stream at the insertion point; for the first content not matching the target content, blocking the insertion of the second content; and for the first content not matching the target content, performing the insertion of the second content.

Abstract: The present disclosure generally relates to user interfaces and techniques for managing and visualizing sound reduction using a computer system. In accordance with some embodiments, the computer system displays a representation of a noise level including, in accordance with a sound reduction display option being enabled, a first indication of a noise level at a first time and a second indication of a noise level at a time different from the first time. In accordance with some embodiments, in accordance with a determination that the sound reduction display option is not enabled, an indication of a noise level at the first time that indicates the noise level.

Abstract: The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.